Insulet Names Former J&J MedTech Exec Ashley McEvoy as President, CEO

Insulet has appointed Ashley McEvoy as its new president and CEO, effective immediately.

McEvoy follows Jim Hollingshead, who agreed with the company that his employment will cease as of April 28, and resigned from the board of directors. The board and Hollingshead agreed now is the time to implement the leadership transition, and he entered a consulting arrangement with the company.

From 1996 to 2023, McEvoy was in leadership roles of increasing responsibility at Johnson & Johnson, most recently as executive VP and worldwide chairman of J&J’s MedTech business. Earlier in her tenure, she was company group chairman of Vision and Diabetes Care for six years, worldwide president of Ethicon for three years, and president of McNeil Consumer Healthcare for three years.

Since 2023, McEvoy was a member of Procter & Gamble’s board, serving on the Compensation & Leadership Development and Innovation & Technology Committees. She previously served on the Board of Trustees for the Children’s Hospital of Philadelphia.

“Insulet has transformed diabetes care, and I am honored to join the company as its next CEO,” said McEvoy. “Insulet has massive, untapped growth potential, a talented team, unparalleled pharmacy channel access and manufacturing capabilities, and deeply loyal customers—remarkable differentiators and a strong foundation for continued success. At this critical moment in the Company and market’s evolution, Insulet has a unique opportunity to enhance innovation, drive global expansion, and win the hearts and minds of more providers and consumers by thinking differently about the experiences and needs of people with diabetes. I am excited to work alongside Insulet’s accomplished team to do just that—and in the process, continue to revolutionize diabetes care and make life easier for people living with diabetes, while driving value creation for shareholders.”

“It has been a privilege to serve as Insulet’s CEO,” said Hollingshead. “I am immensely proud of what our team has accomplished in redefining diabetes care through the simplicity and sophistication of the Omnipod platform. I will be forever grateful to all of my colleagues at Insulet for their passion and dedication for improving and simplifying lives for people living with diabetes, which has led us to tremendous success, and more importantly helped us to reach hundreds of thousands of customers all over the world. I look forward to seeing all that will be achieved going forward.”